Hyderabad, July 20 (Hydnow): Dr Reddy’s Laboratories Limited said on Saturday it has closed the transaction with Upsher-Smith Laboratories (Upsher-Smith), pursuant to the satisfactory completion of all customary closing conditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended.
Dr Reddy’s Laboratories announced on June 14 that it has entered into a definitive asset purchase agreement with Upsher-Smith, pursuant to which Dr Reddy’s would sell its US and select territory rights for Zembrace Symtouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg, (formerly referred to as “DFN-02”), which are commercialised through its wholly owned subsidiary, Promius Pharma. (Hydnow)